Diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration) which may cause kidney problems
however, the exact mechanism of their association with palmitoylation is unclear
Although the SAVOR and EXAMINE studies were delineated to verify cardiovascular safety of two DPP-4i, namely saxagliptin and alogliptin, respectively, both are considered to be the first controlled clinical trials to address the effect of GLP-1 system on CVD
The glucagon component of retatrutide appears to drive this effect, as glucagon promotes hepatic fat oxidation, essentially telling the liver to burn its own stored fat
Some users may notice improvements in appetite control and digestion within weeks, while others may take longer to experience changes
In aggregate the survey found that GLP-1 households reduced their unit purchases of food at rates higher than non-GLP-1 households, principally due to those patients on the drug for weight loss, which is intuitive (if you want to lose weight, you cut calories)